Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) rose 12.2% during trading on Monday . The stock traded as high as $13.99 and last traded at $13.71. Approximately 159,948 shares traded hands during trading, a decline of 54% from the average daily volume of 346,913 shares. The stock had previously closed at $12.22.

NRIX has been the topic of several research analyst reports. Royal Bank of Canada  restated an “outperform” rating and set a $30.00 target price on shares of Nurix Therapeutics in a research report on Friday, April 14th. Stifel Nicolaus decreased their target price on shares of Nurix Therapeutics from $37.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, February 14th. Oppenheimer started coverage on shares of Nurix Therapeutics in a research report on Monday, February 27th. They set an “outperform” rating and a $25.00 target price on the stock. Barclays started coverage on shares of Nurix Therapeutics in a research report on Thursday, March 9th. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Nurix Therapeutics from $37.00 to $36.00 and set an “overweight” rating on the stock in a research report on Monday, February 13th. One investment analyst  has rated the stock with a hold rating and ten have issued  a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $29.75.

The firm’s 50 day moving average is $9.56 and its two-hundred day moving average is $11.12.

Nurix Therapeutics (NASDAQ:NRIX – Get Rating) last announced its earnings results on Thursday, February 9th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.19). Nurix Therapeutics had a negative net margin of 428.29% and a negative return on equity of 60.17%. The firm had revenue of $6.78 million during the quarter, compared to analyst estimates of $19.64 million.  Equities analysts expect that  Nurix Therapeutics, Inc. will post -3.36 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in NRIX. Credit Suisse AG increased its stake in shares of  Nurix Therapeutics by 7.9% during the 2nd quarter. Credit Suisse AG now owns 15,619 shares of the company’s stock valued at $197,000 after acquiring an additional 1,145 shares during the last quarter.  Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of  Nurix Therapeutics by 23.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,312 shares of the company’s stock valued at $69,000 after acquiring an additional 1,194 shares during the last quarter.  Rhumbline Advisers increased its stake in shares of  Nurix Therapeutics by 4.9% during the 1st quarter. Rhumbline Advisers now owns 33,511 shares of the company’s stock valued at $469,000 after acquiring an additional 1,573 shares during the last quarter.  Tudor Investment Corp Et Al increased its stake in shares of  Nurix Therapeutics by 9.1% during the 3rd quarter. Tudor Investment Corp Et Al now owns 22,197 shares of the company’s stock valued at $289,000 after acquiring an additional 1,848 shares during the last quarter.  Finally, Great West Life Assurance Co. Can acquired a new position in shares of  Nurix Therapeutics during the 3rd quarter valued at about $25,000. Institutional investors and hedge funds own  91.33% of the company’s stock.

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.